Long-term femoral vein central venous access in cancer patients.
Subclavian percutaneous access with reservoir placement has been shown to be difficult or contraindicated in some patients. Of 465 cancer patients who required a port placement between January 1992 to January 1995, 41 (8.8%) had alternative percutaneous femoral access with a totally implantable port reservoir located in the abdomen because of the inaccessibility to subclavian or jugular veins and/or the presence of massive cutaneous metastases or severe radiodermitis in the upper part of the torso. Overall implant days was 9880, with an average of 241 days (range: 65-445). Ports were alternatively used for chemotherapy and nutritional purposes in 11 of 41 patients. Late morbidity causing the removal of the implanted ports was observed in two of 41 (4.9%) and 25 of 424 (5.9%) patients in the femoral and subclavian series, respectively (P = 0.86). The femoral percutaneous access for totally implantable port devices appears to be a safe alternative for cancer patients when subclavian and/or jugular vein catheterization and reservoir in the upper part of the torso is contraindicated.
Bertoglio
S
S
Institute of Clinical and Experimental Oncology, University of Genoa, Italy.
DiSomma
C
C
Meszaros
P
P
Gipponi
M
M
Cafiero
F
F
Percivale
P
P
D000328:Adult; D000368:Aged; D002408:Catheters, Indwelling / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D005268:Femoral Vein; D006801:Humans; D007601:Jugular Veins; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D013350:Subclavian Vein; D013997:Time Factors